Number of employees
120
Annual revenue
$6500000
Coley Pharmaceutical Group discovers, develops and commercializes TLR Therapeutics (tm), a new class of drugs that direct the immune system to treat chronic diseases. Coley's pipeline features clinical stage products to treat cancers, infectious diseases, and asthma and allergy.